Bristol-Myers Squibb Co (LIM:BMY) Moat Score: 8/10 (As of Jul. 06, 2026)


LIM:BMY Bristol-Myers Squibb Co LIM:BMY
57 GF Score
Price $56.98
GF Value $48.23
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Moat Score?

Bristol-Myers Squibb Co LIM:BMY 57 Moat Score is 8 as of Jul. 06, 2026. GuruFocus rates LIM:BMY with a GF Score™ of 57/100 and a GF Value™ of $48.23 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 99.71% on this metric.

Bristol-Myers Squibb Co has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Bristol-Myers Squibb Co has Wide Moat: Bristol-Myers Squibb Co has a robust portfolio of patents, strong R&D capabilities, and significant pricing power in the pharmaceutical industry. It benefits from regulatory exclusivity and a strong brand, providing a clear and robust wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bristol-Myers Squibb Co might have Wide Moat - Clear and robust wide moat.

Bristol-Myers Squibb Co  (LIM:BMY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bristol-Myers Squibb Co Moat Score Related Terms

LIM:BMY vs PFE, GILD, AMGN: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bristol-Myers Squibb Co Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Moat Score falls into.


LIM:BMY
57GF Score
Bristol-Myers Squibb Co LIM:BMY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
Bristol-Myers Squibb Co (LIM:BMY) has a Moat Score of 8 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #3 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Bristol-Myers Squibb Co's Moat Score too high?
Bristol-Myers Squibb Co's current Moat Score is 8. Based on the distribution chart, Bristol-Myers Squibb Co ranks #3 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Moat Score compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #3 out of 1032 companies for Moat Score. This places Bristol-Myers Squibb Co in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Bristol-Myers Squibb Co's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.23, compared to a current price of $56.98 — trading 18.1% above its estimated fair value. The current Moat Score is 8. Bristol-Myers Squibb Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current Moat Score is 8 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of $56.98 is trading 18.1% above its estimated GF Value™ of $48.23. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for LIM:BMY:

  • Moat Score: 8
  • GF Value™: $48.23 vs. price of $56.98 (18.1% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
57GF Score

Get the complete analysis for LIM:BMY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.98
Price
$48.23
GF Value